OakChart

CVRx Inc

CVRXHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 11:44 AM ET

0.7085+0.0132 (1.90%)
2026-11-11 17:45 CET
Market cap
19.81 USD m
Revenue, TTM
60.33 USD m
Net income, TTM
-53.26 USD m
Free cash flow, TTM
-42.05 USD m
EPS diluted, TTM
-2.00
P/E
-
Compare

Price

CVRX against its 20, 50 and 200-day averages
2050200beatearnings
2.004.006.008.007.4M14.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CVRXclose 0.7120-day 1.2850-day 1.95200-day 5.070.71

93.1% under the 52-week high of 10.28 on 25 Nov 2025. 52-week low 0.67 on 10 Nov 2026. Last 15 sessions, 137.4% high to low

Profile

CVRX
52-week range, 0% of the way up
0.6710.28

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.

IndexRUT
Employees223
IPOJun 30, 2021
Beta0.83
ATR, 14d0.18
Rel volume0.39
Short float10.50%
Insider own39.19%
Inst own30.14%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap20.19M
Enterprise Value20.82M
Income-53.26M
Sales60.33M
Book/sh0.49
Cash/sh2.06
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees223
IPOJun 30, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S0.33
P/B1.46
P/C0.34
P/FCF-
EV/EBITDA-
EV/Sales0.35
Quick Ratio5.71
Current Ratio6.80
Debt/Eq4.30
LT Debt/Eq4.27
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.00
EPS next Y-1.90
EPS next Q-0.52
EPS this Y-0.97%
EPS next Y7.86%
EPS next 5Y8.64%
EPS past 3/5Y-0.43% -22.44%
Sales past 3/5Y36.11% 56.40%
EPS Y/Y TTM0.87%
Sales Y/Y TTM7.79%
EPS Q/Q-5.69%
Sales Q/Q-5.84%
EarningsNov 05 AMC
EPS/Sales Surpr.-4.92% -0.72%

Ownership

Insider Own39.19%
Insider Trans0.22%
Inst Own30.14%
Inst Trans3.33%
ROA-53.55%
ROE-172.17%
ROIC-73.14%
Gross Margin85.54%
Oper. Margin-81.90%
Profit Margin-88.28%
SMA20-44.53%
SMA50-63.62%
SMA200-86.03%
Trades-

Technical

Shs Outstand28.49M
Shs Float17.32M
Short Float10.50%
Short Ratio2.17
Short Interest1.82M
52W High10.28 -93.11%
52W Low0.67 5.15%
Volatility28.49% 13.29%
ATR (14)0.18
RSI (14)22.82
Beta0.83
Rel Volume0.39
Avg Volume836.45K
Volume123,912

Performance

Perf Week-55.16%
Perf Month-47.90%
Perf Quarter-75.90%
Perf Half Y-86.43%
Perf YTD-90.02%
Perf Year-92.80%
Perf 3Y-95.83%
Perf 5Y-96.18%
Perf 10Y-
Recom3.00
Target Price2.25
Prev Close0.70
Price0.71
Change %1.90%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
Nov 06, 2026DowngradeWWilliam BlairOutperform → Mkt Perform
Nov 06, 2026DowngradeCCanaccord GenuityBuy → Hold$2+182.3%
Aug 07, 2026DowngradePPiper SandlerOverweight → Neutral$4+464.6%
Aug 07, 2026DowngradeLLake StreetBuy → Hold$3.50+394.0%
Aug 07, 2026DowngradeCCraig HallumBuy → Hold$4+464.6%
May 09, 2025DowngradeJJP MorganNeutral → Underweight$7+888.0%
Jan 14, 2025UpgradeWWilliam BlairMkt Perform → Outperform
Sep 10, 2024InitiatedCCantor FitzgeraldOverweight$14+1,876.0%
Jul 11, 2024ReiteratedLLake StreetBuy$18 → $12+1,593.7%
May 01, 2024ResumedCCraig HallumBuy$30 → $23+3,146.3%

Peers

Mkt cap
TickerCompanyMkt cap
INSPInspire Medical Systems Inc1.78B
NYXHNyxoah SA90.30M
LIVNLivaNova PLC4.98B
NPCENeuroPace Inc440.04M
ECORElectroCore Inc75.92M
IRTCiRhythm Holdings Inc2.98B
BSXBoston Scientific Corp66.34B
MDTMedtronic Plc129.39B
BWAYBrainsway Ltd ADR440.94M
SNWVSanuwave Health Inc13.85M

Insider trading

13 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Binkowski BrentCHIEF OPERATING OFFICERAug 13 '26Buy2.9126,22376,43256,514Aug 13 08:18 PM
Binkowski BrentCHIEF OPERATING OFFICERAug 12 '26Sale2.551,3093,33830,291Aug 13 04:26 PM
Adamson Philip B.Chief Medical OfficerMar 02 '26Sale7.901,2629,97361,578Mar 16 04:16 PM
Hykes KevinPRES & CEOMar 02 '26Sale7.907,76361,349284,237Mar 03 06:03 PM
VERRASTRO PAULCHIEF MKTG & STRAT OFFICERMar 02 '26Sale7.901,28410,14660,551Mar 03 06:03 PM
OASHEIM JAREDCHIEF FINANCIAL OFFICERMar 02 '26Sale7.901,74413,78196,703Mar 03 06:02 PM
John Robert AllenChief Revenue OfficerMar 02 '26Sale7.903,96431,32686,036Mar 03 06:01 PM
Jain Mudit K.DirectorFeb 20 '26Buy6.3646,800297,592980,183Feb 23 06:00 AM
Jain Mudit K.DirectorFeb 18 '26Buy4.646002,7855,650Feb 18 05:22 PM
JOHNSON & JOHNSON10% OwnerNov 26 '25Sale10.036,33763,5604,040,861Dec 01 04:07 PM
JOHNSON & JOHNSON10% OwnerNov 24 '25Sale10.062,20022,1324,047,198Nov 25 12:54 PM
JOHNSON & JOHNSON10% OwnerNov 21 '25Sale10.005005,0004,049,398Nov 25 12:54 PM
JOHNSON & JOHNSON10% OwnerNov 12 '25Sale10.001,00010,0004,049,898Nov 14 03:07 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
RSSLGlobal X Russell 2000 ETFAUM: 1.43B

News

latest 14 of 206
  • CVRx Cuts Guidance Again As Payer Friction Pushes Growth Into Reverse And Implied Q4 Plunges (Earnings Whispers) -6.96% -40.90%
  • CVRx: Q3 Earnings Snapshot (Associated Press)
  • CVRx Reports Third Quarter 2026 Financial and Operating Results (GlobeNewswire)
  • CVRx to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • CVRx Faces A Credibility Test As Sales-Force Repairs Meet A Lowered Revenue Bar (Earnings Whispers)
  • Loading…
  • CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026 (GlobeNewswire)
  • CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026 (GlobeNewswire) -33.46%
  • CVRx Appoints John Landry as Chief Financial Officer (GlobeNewswire)
  • CVRx Responds to Letter from Pointillist Family Office (GlobeNewswire) +6.98%
  • CVRx, Inc. Investors Who Suffered Losses Should Contact Block & Leviton LLP (Newsfile) +10.92%
  • Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer (PR Newswire)
  • CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy (GlobeNewswire)
  • CVRx Announces Sales Leadership Transition (GlobeNewswire) +9.70%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.520-0.496-0.52013.8313.937
2026Q22026-08-06-0.530-0.525-0.53015.7115.557
2026Q12026-05-11-0.500-0.504-0.49814.7714.497
2025Q42026-02-12-0.460-0.439-0.45516.0215.787
2025Q32025-11-05-0.490-0.493-0.49214.6914.407
2025Q22025-08-04-0.570-0.520-0.56513.5913.297
2025Q12025-05-08-0.530-0.570-0.53212.3513.387
2024Q42025-02-04-0.430-0.375-0.43115.3415.077
2024Q32024-10-29-0.570-0.504-0.57513.3713.187
2024Q22024-07-29-0.650-0.546-0.64911.8111.806
2024Q12024-05-01-1.040-0.541-1.04510.7711.426
2023Q42024-01-25-0.440-0.545-0.44011.3111.146
2023Q32023-10-26-0.430-0.578-0.43310.519.826
2023Q22023-07-25-0.560-0.583-0.5639.508.596
2023Q12023-04-27-0.550-0.566-0.5507.987.206
2022Q42023-01-26-0.510-0.555-0.5127.186.975

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-4.160-4.047-2.11213.0413.25
2022FY-2.020-2.062-2.01822.4722.21
2023FY-1.990-2.090-1.98539.3039.14
2024FY-2.650-2.558-2.65451.2951.01
2025FY-2.040-2.029-2.04056.6556.39
2026FY--2.051--57.02
2027FY--1.889--60.40
2028FY--1.555--71.10
2029FY--1.245--89.84
2030FY--1.130--123

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0670512.7611.6514.68
2026Q4S2026-10-2870014.4614.0015.16
2026Q4S2026-10-2170114.4614.0015.16
2026Q4S2026-09-1870714.4614.0015.16
2026Q4S2026-09-1170714.4614.0015.16
2026Q4S2026-08-1470714.4714.0015.16
2026Q4S2026-08-0770614.9814.0018.30
2026Q4S2026-07-2670018.1417.2818.83
2026Q4S2026-07-1472118.1417.2818.83
2026Q4S2026-07-0372118.1417.2818.83
2026Q4S2026-07-0272118.1417.2818.83
2026Q4S2026-06-2972118.1417.2818.83
2026Q4S2026-06-2473118.1417.2818.83
2026Q4S2026-06-0873218.1417.2818.83

Estimate history

EPS, annual-0.759-0.743-2.112-2.018-1.985-2.654-2.044-2.0024
Period2019202020212022202320242025TTM
EPS, quarterly-0.575-0.431-0.532-0.565-0.492-0.455-0.498-0.53-0.52
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual6.2576.05313.03622.46939.29551.29256.65160.33
Period2019202020212022202320242025TTM
Sales, quarterly13.37315.34212.34813.58914.6916.02414.76915.70513.832
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual19.29519.29520.39920.63420.87925.32526.31228.485
Period2019202020212022202320242025MRQ
Shares, quarterly24.20425.32526.05226.14626.19426.31226.42926.64228.485
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue60.3356.6551.2939.3022.4713.046.056.26
Cost of Goods Sold Incl. D&A8.729.078.956.785.413.811.511.74
Gross Profit51.6147.5842.3432.5217.069.234.544.52
Selling, General and Administrative Excl. Other101.0298.85101.8375.6259.5935.2016.0514.71
Research and Development11.8711.1311.1311.639.957.506.418.66
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-49.41-51.27-59.49-43.10-42.53-25.97-11.51-10.19
Interest Expense6.155.834.401.800.172.222.471.72
Unusual Expense0.000.000.000.000.0013.290.000.00
Net Income Before Taxes-53.27-53.32-59.91-41.05-41.32-42.99-14.02-14.56
Income Taxes-0.00-0.020.060.150.110.090.090.07
Consolidated Net Income-53.26-53.31-59.97-41.20-41.43-43.08-14.33-14.65
Net Income From Continuing Operations-53.26-53.31-59.97-41.20-41.43-43.08-14.33-14.65
Net Income-53.26-53.31-59.97-41.20-41.43-43.08-14.33-14.65
EPS (Recurring)-1.95-2.04-2.65-1.99-2.02-1.66-0.74-0.76
EPS (Basic, Before Extraordinaries)-2.00-2.04-2.65-1.99-2.02-2.11-0.74-0.76
EPS (Diluted)-2.00-2.04-2.65-1.99-2.02-2.11-0.74-0.76
EBITDA-48.59-50.51-58.87-42.58-42.12-25.80-11.44-10.14
Non-Operating Income (Expense)2.303.773.983.851.37-1.51-0.04-2.65
Other After Tax Adjustments0.000.000.000.000.000.00-0.22-0.01
Stock Option Compensation Expense9.678.7315.054.983.071.400.100.05
Price To Sales Ratio0.793.275.5816.6116.7719.14--
Gross Margin85.5483.9982.5582.7575.9270.7974.9772.21
Operating Margin-81.90-90.49-115.98-109.69-189.27-199.20-190.22-162.92
Net Margin-88.28-94.10-116.91-104.85-184.38-330.45-236.68-234.07
Shares Outstanding28.4926.3125.3220.8820.6320.4019.2919.29
Market Capitalization19.8119.81307.42654.44377.72248.90240.76-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue13.8315.7114.7716.0214.6913.5912.3515.34
Cost of Goods Sold Incl. D&A2.052.192.092.382.132.332.222.75
Gross Profit11.7813.5212.6813.6412.5611.2610.1312.59
Selling, General and Administrative Excl. Other24.8226.5424.8424.8224.8325.6323.5722.87
Research and Development2.653.133.083.003.152.472.522.81
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-13.04-13.02-12.16-11.18-12.27-14.38-13.44-10.27
Interest Expense1.611.581.551.421.481.471.461.52
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-14.16-14.04-13.12-11.94-12.87-14.74-13.77-10.72
Income Taxes-0.000.000.00-0.01-0.00-0.00-0.01-0.07
Consolidated Net Income-14.16-14.04-13.12-11.93-12.87-14.74-13.77-10.65
Net Income From Continuing Operations-14.16-14.04-13.12-11.93-12.87-14.74-13.77-10.65
Net Income-14.16-14.04-13.12-11.93-12.87-14.74-13.77-10.65
EPS (Recurring)-0.52-0.53-0.50-0.46-0.49-0.57-0.53-0.43
EPS (Basic, Before Extraordinaries)-0.52-0.53-0.50-0.46-0.49-0.57-0.53-0.43
EPS (Diluted)-0.52-0.53-0.50-0.46-0.49-0.57-0.53-0.43
EBITDA-12.82-12.81-11.96-11.00-12.07-14.18-13.25-10.10
Non-Operating Income (Expense)0.490.560.590.660.881.111.121.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.272.892.302.212.282.301.942.12
Price To Sales Ratio0.792.234.223.293.772.815.996.11
Gross Margin85.1586.0685.8385.1285.4982.8482.0282.08
Operating Margin-94.31-82.92-82.34-69.80-83.51-105.79-108.82-66.97
Net Margin-102.39-89.42-88.83-74.48-87.61-108.44-111.48-69.42
Shares Outstanding28.4926.6426.4326.3126.1926.1526.0525.32
Market Capitalization19.81136.39248.91186.09211.04153.31318.42307.42

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments75.71105.9390.57106.19142.0759.1125.74
Short Term Receivables10.669.277.555.502.561.280.72
Inventories12.2112.1110.986.963.883.342.07
Other Current Assets3.072.502.994.222.580.600.38
Total Current Assets101.65129.81112.09122.88151.1064.3428.91
Net Property, Plant & Equipment3.123.573.112.031.430.410.17
Total Investments and Advances0.000.000.000.000.000.000.00
Other Assets0.030.030.030.030.030.030.03
Total Assets104.79133.41115.23124.94152.5564.7829.11
Short Term Debt Incl. Current Port. of LT Debt0.350.280.230.220.000.000.00
Accounts Payable3.832.581.881.720.510.480.44
Income Tax Payable0.090.140.120.120.35--
Other Current Liabilities9.047.765.626.035.057.498.18
Total Current Liabilities13.3210.767.868.095.917.988.61
Long Term Debt50.1550.1530.386.860.00349.26298.98
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities2.001.451.040.810.680.780.56
Total Liabilities65.4762.3639.2815.766.59358.01308.15
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity39.3271.0675.95109.18145.96-293.24-279.04
Total Shareholders Equity39.3271.0675.95109.18145.96-293.24-279.04
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity39.3271.0675.95109.18145.96-293.24-279.04
Total Liabilities & Stockholders Equity104.79133.41115.23124.94152.5564.7829.11
Book Value Per Share1.492.813.645.297.16-15.20-14.46
Tangible Book Value Per Share1.492.813.645.297.16-15.20-14.46
Full-Time Employees22320620016010963-
Price to Book Ratio1.434.707.903.191.711.55-
Return on Assets-44.76-48.23-34.31-29.86-39.64-30.52-
Return on Equity-96.59-81.58-44.51-32.47---
Return on Invested Capital-59.58-49.47-38.75-35.70-29.51-25.57-73.48
Quick Ratio6.7210.9412.8614.3324.927.653.12
Current Ratio7.6312.0614.2515.1925.578.073.36

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-53.26-53.31-59.97-41.20-41.43-43.08-14.11-14.63
Depreciation0.820.760.620.520.410.170.070.06
Other Funds (Non Cash)12.6511.3819.256.463.9116.760.793.13
Funds from Operations-39.80-41.17-40.09-34.22-37.10-26.15-13.24-11.45
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-1.851.000.95-4.80-5.57-1.58-2.85-1.33
Cash from Operating Activities-41.65-40.17-39.14-39.02-42.68-27.73-16.10-12.79
Capital Expenditures-0.40-0.58-1.36-0.59-0.69-1.18-0.31-0.11
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.40-0.58-1.36-0.59-0.69-1.18-0.31-0.11
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock6.7810.5236.021.668.27133.1849.7824.69
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock6.7810.5236.021.668.27133.1849.7824.69
Proceedsfrom Stock Options6.529.7333.320.948.09133.1849.7824.69
Issuance or Reduction of Debt, Net8.890.0019.8522.320.00-21.300.004.86
Change in Long Term Debt8.890.0019.8522.320.00-21.300.004.86
Issuance of Long Term Debt8.890.0019.8522.320.000.000.0019.52
Reduction of Long Term Debt0.000.000.000.000.00-21.300.00-14.66
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.000.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.000.000.00
Cash from Financing Activities15.6710.5255.8723.987.49111.8849.7829.55
Exchange Rate Effect-0.000.01-0.000.00-0.01-0.01-0.01-0.01
Net Change in Cash-26.38-30.2315.36-15.62-35.8882.9633.3716.65
Free Cash Flow-42.05-40.75-40.51-39.61-43.36-28.91-16.41-12.89
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments58.7564.5972.3075.7185.1295.03
Short Term Receivables9.599.409.1010.668.217.15
Inventories13.6313.0312.4012.2111.3911.72
Other Current Assets3.062.472.943.073.162.25
Total Current Assets85.0289.4996.75101.65107.89116.14
Net Property, Plant & Equipment2.562.772.953.123.413.39
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.030.030.030.030.030.03
Total Assets87.6192.2899.73104.79111.33119.56
Short Term Debt Incl. Current Port. of LT Debt0.380.370.360.350.340.33
Accounts Payable4.143.873.003.833.633.03
Income Tax Payable0.070.050.130.090.130.05
Other Current Liabilities7.916.836.009.047.126.28
Total Current Liabilities12.5111.129.4913.3211.229.69
Long Term Debt59.0059.0259.0350.1550.1850.21
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.282.192.102.001.871.73
Total Liabilities73.7972.3370.6265.4763.2761.63
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity13.8219.9529.1139.3248.0557.93
Total Shareholders Equity13.8219.9529.1139.3248.0557.93
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity13.8219.9529.1139.3248.0557.93
Total Liabilities & Stockholders Equity87.6192.2899.73104.79111.33119.56
Book Value Per Share0.490.751.101.491.832.22
Tangible Book Value Per Share0.490.751.101.491.832.22
Full-Time Employees---223--
Price to Book Ratio1.434.676.333.873.642.21
Return on Assets-53.55-49.06-45.93-44.76-43.53-48.48
Return on Equity-172.17-133.44-106.96-96.59-91.88-92.33
Return on Invested Capital-19.45-17.78-14.88-13.34-13.10-13.63
Quick Ratio5.716.878.896.728.6010.78
Current Ratio6.808.0410.207.639.6211.99

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-14.16-14.04-13.12-11.93-12.87-14.74
Depreciation0.220.210.200.180.190.19
Other Funds (Non Cash)2.963.753.002.942.952.98
Funds from Operations-10.99-10.09-9.91-8.81-9.73-11.57
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.091.26-2.25-0.950.023.63
Cash from Operating Activities-10.90-8.83-12.16-9.76-9.71-7.94
Capital Expenditures-0.10-0.11-0.12-0.07-0.29-0.10
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.10-0.11-0.12-0.07-0.29-0.10
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock5.161.22-0.010.410.100.39
Repurchase of Common Pref Stock0.000.04-0.040.000.000.00
Sale of Common Pref Stock5.161.180.030.410.100.39
Proceedsfrom Stock Options5.161.150.000.21-0.040.36
Issuance or Reduction of Debt, Net-0.00-0.008.890.000.000.00
Change in Long Term Debt-0.00-0.008.890.000.000.00
Issuance of Long Term Debt-0.00-0.008.890.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities5.161.228.880.410.100.39
Exchange Rate Effect0.000.00-0.000.000.000.00
Net Change in Cash-5.84-7.72-3.40-9.42-9.90-7.64
Free Cash Flow-10.99-8.94-12.29-9.83-10.00-8.04

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 51.29M 2025: 56.65M
Germany2024: 4.13M 2025: 4.77M
United States2024: 47.17M 2025: 51.88M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.50%1.8M17.3M950.88K
2026-10-1513.19%2.1M16.2M937.70K
2026-09-3012.24%2.0M16.2M866.72K
2026-09-1511.03%1.6M14.9M790.28K
2026-08-3113.25%2.0M14.9M729.07K
2026-08-1417.31%2.4M13.6M651.45K
2026-07-3113.36%2.0M15.0M311.23K
2026-07-1512.86%1.9M15.0M315.64K
2026-06-3012.28%1.8M15.0M321.11K
2026-06-1511.72%1.8M15.0M300.84K
2026-05-2913.06%1.9M14.9M292.15K
2026-05-1512.56%1.9M15.2M350.26K
2026-04-3011.95%1.7M14.6M318.35K
2026-04-1511.48%1.7M14.5M354.66K
2026-03-3111.45%1.7M14.8M357.32K
2026-03-1312.08%1.8M14.8M352.15K
2026-02-2713.06%1.9M14.8M332.16K
2026-02-1310.20%1.5M14.8M275.92K
2026-01-3010.40%1.6M15.8M274.44K
2026-01-158.43%1.3M15.8M225.77K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.056.0042090.000.196-0.0100.000
call5.000.001.750.057.85910.000.000.170-0.0120.000
call7.500.001.750.058.8365.000.000.160-0.0130.000
put2.501.202.350.0020.0070.000.00-0.806-0.0100.000
put5.002.356.800.000.0000.000.00-0.830-0.0120.000
put7.506.007.500.000.0000.000.00-0.840-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-02SCHEDULE 13D/ASEC
2026-09-218-KCurrent report2026-09-16SEC
2026-08-24SCHEDULE 13DSEC
2026-08-14SCHEDULE 13GSEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-118-KCurrent report2026-08-10SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-06-098-KCurrent report2026-06-07SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-033Initial statement of beneficial ownership of securities2026-06-01SEC
2026-06-038-KCurrent report2026-06-01SEC
2026-05-28SDSpecialized Disclosure ReportSEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-04-20DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-20DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-01SEC
2026-04-138-KCurrent report2026-04-13SEC
2026-03-164Statement of changes in beneficial ownership of securities2026-02-27SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0876.43K13.34K1
2026-070000
2026-060000
2026-050000
2026-040000
2026-0300126.58K5
2026-02300.38K200
2026-010000
2025-120000
2025-1100637.00K6

Institutional holders

Manager% owned
JOHNSON & JOHNSON15.11%
NEA Management Company, LLC7.37%
BlackRock, Inc.4.69%
ROYAL BANK OF CANADA4.65%
GSK plc3.78%
VANGUARD CAPITAL MANAGEMENT LLC3.43%
SILVERCREST ASSET MANAGEMENT GROUP LLC3.31%
GEODE CAPITAL MANAGEMENT, LLC1.59%
PFM Health Sciences, LP1.39%
STATE STREET CORP1.38%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.58%
iShares Russell 2000 ETF1.40%
VANGUARD EXTENDED MARKET INDEX FUND0.77%
Fidelity Small Cap Index Fund0.63%
iShares Russell 2000 Growth ETF0.59%
Fidelity Extended Market Index Fund0.35%
VANGUARD RUSSELL 2000 INDEX FUND0.33%
iShares Micro-Cap ETF0.19%
Goldman Sachs Absolute Return Tracker Fund0.16%
Ultra-Small Company Market Fund0.14%

OakChart. CVRX. Cached 15 minutes.